Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:42:05.506Z.
Calculation as of: 2026-10-06T19:42:05.506Z.
Quote observation: 2026-10-06T19:40:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$27.65M
EV/Sales Ratio
36.48x
TTM Avg
235.31x
3Y Avg
882.90x
5Y Avg
492.34x
Market Cap
$27.93M
EV/Sales Ratio
121.44x
TTM Avg
354.15x
3Y Avg
539.01x
5Y Avg
539.01x
Market Cap
$24.51M
EV/Sales Ratio
N/A
TTM Avg
8660.16x
3Y Avg
2951.18x
5Y Avg
1830.92x
Market Cap
$24.59M
EV/Sales Ratio
N/A
TTM Avg
390.99x
3Y Avg
224.70x
5Y Avg
223.08x
Market Cap
$28.93M
EV/Sales Ratio
20.11x
TTM Avg
66.22x
3Y Avg
47.59x
5Y Avg
61.65x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $26.49M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.65M | 36.48x | 235.31x | 882.90x | 492.34x |
| aTyr Pharma, Inc. (ATYR)vs › | $27.93M | 121.44x | 354.15x | 539.01x | 539.01x |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.51M | N/A | 8660.16x | 2951.18x | 1830.92x |
| InspireMD, Inc. (NSPR)vs › | $24.60M | 1.05x | 8.15x | 11.91x | 8.44x |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.59M | N/A | 390.99x | 224.70x | 223.08x |
| OneMedNet Corporation (ONMD)vs › | $28.93M | 20.11x | 66.22x | 47.59x | 61.65x |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $28.94M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $23.96M | N/A | 1.44x | 1.04x | 4.23x |
| BeyondSpring Inc. (BYSI)vs › | $29.20M | N/A | 70.91x | 45.25x | 208.18x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
